Greenwich LifeSciences (GLSI) Interest & Investment Income (2021 - 2025)
Greenwich LifeSciences (GLSI) posted Interest & Investment Income of $22258.0 for Q4 2025, down 2.36% on a QoQ basis from $22797.0 in Q3 2025, and down 49.35% year-over-year from $43942.0 in Q4 2024.
Greenwich LifeSciences (GLSI) Interest & Investment Income (2021 - 2025) Analysis & Trends
Greenwich LifeSciences' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $22258.0 for Q4 2025.
- Quarterly Interest & Investment Income fell 49.35% year-over-year to $22258.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $89700.0 (down 59.78% YoY) and the FY2025 annual result came in at $89700.0, down 59.78% from the prior year.
- Interest & Investment Income was $22258.0 for Q4 2025 at Greenwich LifeSciences, down from $22797.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $119453.0 in Q2 2023 and bottomed at $3568.0 in Q3 2021.
- A 5-year average of $49557.8 and a median of $35588.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 1694.76% — and 2025, when it slumped 62.55%.
- Greenwich LifeSciences' Interest & Investment Income stood at $16501.0 in 2021, then surged by 531.3% to $104171.0 in 2022, then slipped by 14.28% to $89294.0 in 2023, then slumped by 50.79% to $43942.0 in 2024, then sank by 49.35% to $22258.0 in 2025.
- Business Quant data shows GLSI's Interest & Investment Income at $22258.0 in Q4 2025, $22797.0 in Q3 2025, and $20675.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Greenwich LifeSciences | 183.67 Mn | 183.67 Mn | - | 22,258.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22,258.00 |
| Sep 30, 2025 | 22,797.00 |
| Jun 30, 2025 | 20,675.00 |
| Mar 31, 2025 | 23,970.00 |
| Dec 31, 2024 | 43,942.00 |
| Sep 30, 2024 | 60,338.00 |
| Jun 30, 2024 | 54,722.00 |
| Mar 31, 2024 | 64,006.00 |
| Dec 31, 2023 | 89,294.00 |
| Sep 30, 2023 | 111,136.00 |
| Jun 30, 2023 | 119,453.00 |
| Mar 31, 2023 | 116,180.00 |
| Dec 31, 2022 | 104,171.00 |
| Sep 30, 2022 | 64,037.00 |
| Jun 30, 2022 | 27,234.00 |
| Mar 31, 2022 | 19,575.00 |
| Dec 31, 2021 | 16,501.00 |
| Sep 30, 2021 | 3,568.00 |
| Jun 30, 2021 | 3,700.00 |
| Mar 31, 2021 | 3,598.00 |